TCM
VERA icon

TimesSquare Capital Management’s Vera Therapeutics VERA Stock Holding History

TimesSquare Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
364,557
+132,094
+57% +$4.92M 0.23% 123
2026
Q1 		$9.35M Sell
232,463
-19,999
-8% -$862K 0.16% 134
2025
Q4 		$12.8M Buy
+252,462
New +$8.97M 0.19% 133

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TimesSquare Capital Management's VERA Position: Q2 2026 in Review

TimesSquare Capital Management increased its Vera Therapeutics (VERA) stake by 57% in Q2 2026, buying an estimated $4.92M and bringing the position to 364,557 shares worth $15.6M. The position accounts for 0.23% of the portfolio, ranked #123.

TimesSquare Capital Management first reported a position in VERA in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • TimesSquare Capital Management held 364,557 shares of Vera Therapeutics worth $15.6M as of Q2 2026.
  • TimesSquare Capital Management bought 132,094 Vera Therapeutics shares in Q2 2026, an estimated $4.92M.
  • Vera Therapeutics made up 0.23% of TimesSquare Capital Management's portfolio in Q2 2026, its #123 holding.
  • TimesSquare Capital Management first reported a position in Vera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.